PNC Financial Services Group Inc. Has $728,000 Stock Position in Bruker Corporation (NASDAQ:BRKR)

PNC Financial Services Group Inc. lowered its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 13.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,453 shares of the medical research company’s stock after selling 2,772 shares during the period. PNC Financial Services Group Inc.’s holdings in Bruker were worth $728,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in BRKR. Pinnacle Bancorp Inc. acquired a new stake in shares of Bruker in the 1st quarter worth about $29,000. Allworth Financial LP raised its holdings in shares of Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after acquiring an additional 364 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company’s stock worth $46,000 after acquiring an additional 800 shares during the last quarter. Fifth Third Bancorp raised its holdings in shares of Bruker by 54.2% in the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company’s stock worth $46,000 after acquiring an additional 390 shares during the last quarter. Finally, UMB Bank n.a. raised its holdings in shares of Bruker by 45.8% in the 1st quarter. UMB Bank n.a. now owns 1,325 shares of the medical research company’s stock worth $55,000 after acquiring an additional 416 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Insider Buying and Selling at Bruker

In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the company’s stock in a transaction that occurred on Friday, June 6th. The shares were acquired at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer directly owned 38,462,171 shares of the company’s stock, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 27.30% of the company’s stock.

Bruker Price Performance

BRKR stock opened at $30.78 on Tuesday. The firm’s 50-day moving average price is $39.33 and its two-hundred day moving average price is $42.24. Bruker Corporation has a 12-month low of $30.00 and a 12-month high of $72.94. The stock has a market capitalization of $4.67 billion, a price-to-earnings ratio of 59.19, a PEG ratio of 2.52 and a beta of 1.16. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The company had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company’s revenue for the quarter was down .4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.52 EPS. As a group, equities analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Citigroup lowered their target price on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, August 4th. Wells Fargo & Company lowered their target price on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Tuesday, August 5th. Barclays lowered their target price on shares of Bruker from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Monday, August 4th. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the stock a “buy” rating in a research report on Monday, August 4th. Finally, The Goldman Sachs Group reduced their price objective on shares of Bruker from $50.00 to $45.00 and set a “neutral” rating for the company in a research report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Bruker has a consensus rating of “Hold” and a consensus price target of $51.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.